Policy + industry dual-drive Innovation drug activation pharmaceutical sector

As the bull market for innovative drugs on the Hong Kong stock market continues to evolve, many mutual fund investors have discovered this year that their medical funds, which have been losing money for years, are starting to make profits. Recently, the Hong Kong stock market's innovative drug sector has remained strong, and the investment value of pharmaceutical stocks and medical funds has once again attracted market attention. Several fund managers believe that the rise in the innovative drug sector of the Hong Kong stock market is not driven by short-term sentiment, but rather a concentrated manifestation of long-term logic such as policy dividends, industrial upgrades, and globalization breakthroughs. Although in the short term, attention needs to be paid to the pace of policy implementation and changes in the external environment, the trend of China's innovative drugs transitioning from "follower" to "leader" has gradually been established, and the revaluation of their value in the global industry chain process is still ongoing. For investors, grasping the main theme of innovative drug internationalization and technological integration, while also considering the logic of undervaluation repair and performance realization, may be key to sharing the dividends of industrial upgrading.